While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.

Roche looks set to gain first and second place in the race to bring CD3Xcd20s to market – but Genmab and AbbVie have a strong challenger.

The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.

Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.

Emerging Company Profile: Swiss biotech Unicyte is using donor-derived liver stem cells across a range of therapeutic areas, with its lead asset showing curative potential in urea cycle disorders.

The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.

Torrent is recalibrating strategy with the addition of chronic therapies from Dr. Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.

Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.

Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.

CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.

Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year. 

Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.

CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.

Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year. 

With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial. 

Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.

According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval. 

While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space. 

The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.

PARP inhibitors are expected to generate $10bn in sales by 2030. Datamonitor Healthcare analysts discuss their positioning in breast, ovarian, pancreatic and prostate cancer, looking at the current market landscape and future strategies.

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.